Literature DB >> 30510007

Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines.

Ximei Sun1,2, Giuseppe Stefanetti1,3, Francesco Berti4, Dennis L Kasper5.   

Abstract

Glycoconjugate vaccines are among the most effective interventions for preventing several serious infectious diseases. Covalent linkage of the bacterial capsular polysaccharide to a carrier protein provides CD4+ T cells with epitopes that facilitate a memory response to the polysaccharide. Classically, the mechanism responsible for antigen processing was thought to be similar to what was known for hapten-carrier conjugates: protease digestion of the carrier protein in the endosome and presentation of a resulting peptide to the T cell receptor on classical peptide-recognizing CD4+ T cells. Recently, an alternative mechanism has been shown to be responsible for the memory response to some glycoconjugates. Processing of both the protein and the polysaccharide creates glycopeptides in the endosome of antigen-presenting cells. For presentation, the peptide portion of the glycopeptide is bound to MHCII, allowing the covalently linked glycan to activate carbohydrate-specific helper CD4+ T cells (Tcarbs). Herein, we assessed whether this same mechanism applies to conjugates prepared from other capsular polysaccharides. All of the glycoconjugates tested induced Tcarb-dependent responses except that made with group C Neisseria meningitidis; in the latter case, only peptides generated from the carrier protein were critical for helper T cell recognition. Digestion of this acid-sensitive polysaccharide, a linear homopolymer of α(2 → 9)-linked sialic acid, to the size of the monomeric unit resulted in a dominant CD4+ T cell response to peptides in the context of MHCII. Our results show that different mechanisms of presentation, based on the structure of the carbohydrate, are operative in response to different glycoconjugate vaccines.

Entities:  

Keywords:  Tcarb; antigen presentation; glycoconjugate; group C Neisseria meningitidis; vaccine

Mesh:

Substances:

Year:  2018        PMID: 30510007      PMCID: PMC6320544          DOI: 10.1073/pnas.1816401115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues.

Authors:  M B Deck; P Sjölin; E R Unanue; J Kihlberg
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

3.  Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens.

Authors:  Dominic F Kelly; Andrew J Pollard; E Richard Moxon
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

Review 4.  Meningococcal polysaccharide-protein conjugate vaccines.

Authors:  Matthew D Snape; Andrew J Pollard
Journal:  Lancet Infect Dis       Date:  2005-01       Impact factor: 25.071

5.  Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates.

Authors:  E C Beuvery; F van Rossum; J Nagel
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

6.  Isolation of carbohydrate-specific CD4(+) T cell clones from mice after stimulation by two model glycoconjugate vaccines.

Authors:  Fikri Y Avci; Xiangming Li; Moriya Tsuji; Dennis L Kasper
Journal:  Nat Protoc       Date:  2012-11-29       Impact factor: 13.491

7.  Polysaccharide processing and presentation by the MHCII pathway.

Authors:  Brian A Cobb; Qun Wang; Arthur O Tzianabos; Dennis L Kasper
Journal:  Cell       Date:  2004-05-28       Impact factor: 41.582

8.  Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.

Authors:  David Pace; Ameneh Khatami; Jennifer McKenna; Danielle Campbell; Simon Attard-Montalto; Jacqueline Birks; Merryn Voysey; Catherine White; Adam Finn; Emma Macloed; Saul N Faust; Alison Louise Kent; Paul T Heath; Ray Borrow; Matthew D Snape; Andrew J Pollard
Journal:  BMJ       Date:  2015-04-01

9.  T Cell-Mediated Humoral Immune Responses to Type 3 Capsular Polysaccharide of Streptococcus pneumoniae.

Authors:  Dustin R Middleton; Lina Sun; Amy V Paschall; Fikri Y Avci
Journal:  J Immunol       Date:  2017-05-31       Impact factor: 5.422

10.  Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses.

Authors:  W E Paul; D H Katz; E A Goidl; B Benacerraf
Journal:  J Exp Med       Date:  1970-08-01       Impact factor: 14.307

View more
  24 in total

Review 1.  Glycoengineering bioconjugate vaccines, therapeutics, and diagnostics in E. coli.

Authors:  Christian M Harding; Mario F Feldman
Journal:  Glycobiology       Date:  2019-07-01       Impact factor: 4.313

2.  On the mechanisms of conjugate vaccines.

Authors:  Rino Rappuoli; Ennio De Gregorio; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-21       Impact factor: 11.205

3.  Isolation and characterization of new human carrier peptides from two important vaccine immunogens.

Authors:  Paeton L Wantuch; Lina Sun; Rachel K LoPilato; Jarrod J Mousa; Robert S Haltiwanger; Fikri Y Avci
Journal:  Vaccine       Date:  2020-01-28       Impact factor: 3.641

4.  Glycan Microarrays Containing Synthetic Streptococcus pneumoniae CPS Fragments and Their Application to Vaccine Development.

Authors:  Paulina Kaplonek; Peter H Seeberger
Journal:  Methods Mol Biol       Date:  2022

5.  On the use of adenovirus dodecahedron as a carrier for glycoconjugate vaccines.

Authors:  Maruthi Prasanna; Malgorzata Podsiadla-Bialoskorska; Damian Mielecki; Nicolas Ruffier; Amina Fateh; Annie Lambert; Mathieu Fanuel; Emilie Camberlein; Ewa Szolajska; Cyrille Grandjean
Journal:  Glycoconj J       Date:  2021-04-14       Impact factor: 2.916

Review 6.  Polysaccharide-based nanomedicines for cancer immunotherapy: A review.

Authors:  Yujun Zeng; Yufan Xiang; Ruilong Sheng; Helena Tomás; João Rodrigues; Zhongwei Gu; Hu Zhang; Qiyong Gong; Kui Luo
Journal:  Bioact Mater       Date:  2021-03-18

7.  Structure and Immunogenicity of the Bordetella pertussis LOS-Derived Oligosaccharides in the Endosomal-Like Pre-Processing Mice Model.

Authors:  Sabina Koj; Karolina Ucieklak; Czeslaw Lugowski; Tomasz Niedziela
Journal:  Vaccines (Basel)       Date:  2021-06-13

Review 8.  Recent advances on smart glycoconjugate vaccines in infections and cancer.

Authors:  Marko Anderluh; Francesco Berti; Anna Bzducha-Wróbel; Fabrizio Chiodo; Cinzia Colombo; Federica Compostella; Katarzyna Durlik; Xhenti Ferhati; Rikard Holmdahl; Dragana Jovanovic; Wieslaw Kaca; Luigi Lay; Milena Marinovic-Cincovic; Marco Marradi; Musa Ozil; Laura Polito; Josè Juan Reina; Celso A Reis; Robert Sackstein; Alba Silipo; Urban Švajger; Ondřej Vaněk; Fumiichiro Yamamoto; Barbara Richichi; Sandra J van Vliet
Journal:  FEBS J       Date:  2021-06-01       Impact factor: 5.622

9.  Total Syntheses of Conjugation-Ready Repeating Units of Acinetobacter baumannii AB5075 for Glycoconjugate Vaccine Development.

Authors:  Shuo Zhang; Peter H Seeberger
Journal:  Chemistry       Date:  2021-11-05       Impact factor: 5.020

Review 10.  Human lung-on-chips: Advanced systems for respiratory virus models and assessment of immune response.

Authors:  Ecem Saygili; Ece Yildiz-Ozturk; Macauley J Green; Amir M Ghaemmaghami; Ozlem Yesil-Celiktas
Journal:  Biomicrofluidics       Date:  2021-03-23       Impact factor: 2.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.